Johnson & Johnson files for FDA approval of oral IL-23 inhibitor in psoriasis New data suggests icotrokinra could challenge injectables with once-daily targeted peptide.

https://www.drugdiscoverynews.com/j-j-files-for-fda-approval-of-oral-il-23-inhibitor-in-psoriasis-16554?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz--zguMfYK2OeIPmZGh66WjttB8dcDG9ZAIFX_txQCJJ0DYGoUyQt754R9KJQADKLAbwiYqNP076k_efJyyvxuCWwx_ttw&_hsmi=388103792&utm_content=388103792&utm_source=hs_email